Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Drop in Short Interest

Posted by Alanna Baker on Feb 4th, 2026

Avalon GloboCare Corp. (NASDAQ:ALBT – Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 96,534 shares, a drop of 13.1% from the December 31st total of 111,024 shares. Based on an average daily volume of 42,481 shares, the days-to-cover ratio is presently 2.3 days. Approximately 2.5% of the company’s shares are short sold. Approximately 2.5% of the company’s shares are short sold. Based on an average daily volume of 42,481 shares, the days-to-cover ratio is presently 2.3 days.

Avalon GloboCare Stock Down 4.4%

Shares of Avalon GloboCare stock opened at $0.70 on Wednesday. The company has a market cap of $2.97 million, a P/E ratio of -0.20 and a beta of -0.06. The firm’s 50 day moving average price is $1.18 and its 200-day moving average price is $1.85. Avalon GloboCare has a 52-week low of $0.66 and a 52-week high of $11.66.

Avalon GloboCare (NASDAQ:ALBT – Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.35 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Avalon GloboCare has a consensus rating of “Sell”.

Get Our Latest Report on ALBT

Avalon GloboCare Company Profile

(Get Free Report)

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.